SRT3025

Sirtris, a GSK Company · Phase 1 active Small molecule

At a glance

Generic name	SRT3025
Sponsor	Sirtris, a GSK Company
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study in Healthy Male Volunteers to Investigate Different Doses of a New Drug for the Treatment of Metabolic Diseases (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SRT3025 CI brief — competitive landscape report
SRT3025 updates RSS · CI watch RSS
Sirtris, a GSK Company portfolio CI